By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH

New Post Public Reply Private Reply Replies (1) Message Board
CyberC undervaluedstocks #56518
684
By Lisa Thompson

NYSESS

READ THE FULL DSS RESEARCH REPORT


Document Security Systems, Inc. (DSS) has long been afflicted with not having enough resources to pursue growth and this past quarter the company took actions to address longer term needs and raised enough cash to last for the next few years, rather than just funding the short term. With new management at the helm, DSS raised a net $5 million in June to fund both increased capacity and fulfill its current orders at two Fortune 100 companies that are in the process of rolling out AuthentiGuard worldwide. For years DSS has been trying to stay profitable while raising small amounts to satisfy cash flow needs, but in one fell swoop, this capital raise should have it set for years, unless of course signing additional large customers again puts a strain on capital.

This new cash is being used by both the printing business, which is increasing capacity by 20% by adding a new folder/gluer, as well as the AuthentiGuard business, which is in the process of installing printers and training personnel at its current customers locations worldwide. The increased capacity in the printing business is expected to add an incremental $2.5 million to revenues in 2019. AuthentiGuard gets paid per label printed, so its revenues will ramp as its customers print and ship product.

On June 10, 2019, DSS sold 11.2 million shares of stock at $0.50 per share for net proceeds of $5 million to fund its strategic objectives. The company has also granted the underwriters a 45-day option to purchase up to 1,680,000 additional shares of common stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions. The company now has approximately 29.2 million shares outstanding.

The company trades at an enterprise value of $9.5 million, which is only 0.5 times EV to its trailing 12-month sales, and we believe the stock has considerable upside as the company shows signs of growth. Based on metrics of its peer group, we believe it is worth $1.66 per share using a blended average EV/sales of 2.1 times and an estimate of $21.5 million in sales in 2019. Any upside from the successful resolution of its IP enforcement efforts has not been factored into this valuation and adds considerable incremental potential for shareholders. Near term we believe announcements of new customer wins could also drive the stock.

Q1 Earnings Shows 10% Sales Growth

DSS reported total Q1 2019 revenues of $4.8 million versus $4.4 million a year ago, up 9.9%. Printed product sales grew 11.3% to $4.4 million as business at the new drug stores increased and new products were offered to customers. Technology sales, services, and licensing declined 2.5% to $443,000, however the Authentiguard part of the business grew 30%. The company is transitioning away from lower margin IT services, especially sales of hardware as a reseller and replacing those sales with its SaaS business.

The GAAP loss per share this year was $0.02 versus a loss of $0.02 a year ago. Non-GAAP it was a loss of $0.02 versus a loss of $0.01. The shares outstanding increased 5.4% to 17.5 million versus 16.6 million in Q1 2018. EBITDA for the quarter was a loss Of $97,000 compared with a positive $15,000 last year. Printed products contributed $395,000 in Q1, while Technology used $324,000.

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 8

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 4

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 7

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 6

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Shareholder Investigations in Various Companies

Updated Category News Views 261

Overview of Current Shareholder Investigations Brodsky & Smith, a well-known litigation law firm, is actively reminding shareholders about various ongoing investigations involving Sealed Air Corporation, Movano Inc., Gulf Island Inc., and Denny's Corporation. If you are a shareholder interested in obtaining more information regarding these investigations, you can reach...

Continue Reading
Nykredit Announces Voluntary Tender Offer for Spar Nord Bank

Updated Category News Views 147

Nykredit Announces a Voluntary Public Tender Offer for Spar Nord Bank Nykredit Realkredit A/S, a prominent player in the Danish financial landscape, has publicly unveiled its plans for a voluntary tender offer directed at Spar Nord Bank A/S. This anticipated offer, which signals Nykredit's strategic expansion ambitions, seeks to acquire all available shares in Spar Nord...

Continue Reading
Big 5 Sporting Goods Embarks on New Growth Journey After Merger

Updated Category News Views 292

Big 5 Sporting Goods Corporation Announces Merger Completion Big 5 Sporting Goods Corporation (Nasdaq: BGFV), a well-established name in the sporting goods industry, has successfully completed its merger with a partnership composed of Worldwide Golf and Capitol Hill Group. This new chapter for Big 5 is expected to propel the company towards greater heights. Merger Details...

Continue Reading
UCB's BIMZELX® Data: A Game Changer for Arthritis Care

Updated Category News Views 132

UCB's Innovative Efforts in Arthritis Treatment UCB is making significant strides in the field of rheumatology, particularly with the release of new data regarding BIMZELX® (bimekizumab-bkzx) presented at the ACR Convergence 2024. This marks the first time the company has shared data specifically relating to psoriatic arthritis (PsA), non-radiographic axial...

Continue Reading
Mega Matrix Launches Captivating Urban Romance on FlexTV

Updated Category News Views 614

Engaging Romance Premieres on FlexTV Mega Matrix Inc. (NYSE American: MPU) has unveiled a captivating romantic miniseries titled A flash Marriage With The Billionaire Tycoon, streaming on its renowned short series platform, FlexTV. This adventurous drama dives into themes of love, responsibility, and the quest for personal redemption, showcasing the complicated lives of...

Continue Reading